van Hell A J, Klymchenko A, Gueth D M, van Blitterswijk W J, Koning G A, Verheij M
Biochim Biophys Acta. 2014 Sep;1841(9):1301-7. doi: 10.1016/j.bbalip.2014.06.006. Epub 2014 Jun 19.
The endothelial lining and its outer lipid membrane are the first major barriers drug molecules encounter upon intravenous administration. Our previous work identified lipid analogs that counteract plasma membrane barrier function for a series of amphiphilic drugs. For example, short-chain sphingolipids (SCS), like N-octanoyl-glucosylceramide, effectively elevated doxorubicin accumulation in tumor cells, both in vitro and in vivo, and in endothelial cells, whereas other (normal) cells remained unaffected. We hypothesize here that local membrane lipid composition and the degree of lipid ordering define SCS efficacy in individual cells. To this end, we study the differential effect of SCS on bovine aortic endothelial cells (BAEC) in its confluent versus proliferative state, as a model system. While their (plasma membrane) lipidome stays remarkably unaltered when BAECs reach confluency, their lipids segregate to form apical and basolateral domains. Using probe NR12S, we reveal that lipids in the apical membrane are more condensed/liquid-ordered. SCS preferentially attenuate the barrier posed by these condensed membranes and facilitate doxorubicin influx in these particular membrane regions. We confirm these findings in MDCK cells and artificial membranes. In conclusion, SCS-facilitated drug traversal acts on condensed membrane domains, elicited by confluency in resting endothelium.
内皮细胞内衬及其外层脂质膜是药物分子静脉给药后遇到的第一道主要屏障。我们之前的研究确定了一系列两亲性药物的脂质类似物,这些类似物能够抵消质膜的屏障功能。例如,短链鞘脂(SCS),如N - 辛酰 - 葡萄糖神经酰胺,在体外和体内以及在内皮细胞中,均能有效提高肿瘤细胞中阿霉素的积累量,而其他(正常)细胞则不受影响。我们在此假设,局部膜脂质组成和脂质有序程度决定了SCS在单个细胞中的功效。为此,我们研究了SCS对处于汇合状态与增殖状态的牛主动脉内皮细胞(BAEC)的不同影响,以此作为一个模型系统。当BAEC达到汇合状态时,其(质膜)脂质组保持显著不变,但其脂质会分离形成顶端和基底外侧结构域。使用探针NR12S,我们发现顶端膜中的脂质更为凝聚/液态有序。SCS优先减弱这些凝聚膜所形成的屏障,并促进阿霉素在这些特定膜区域的流入。我们在MDCK细胞和人工膜中证实了这些发现。总之,SCS促进的药物穿越作用于静止内皮细胞汇合所引发的凝聚膜结构域。